TENNESSEE RETINA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.tnretina.com/
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (100.0%)Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
Phase 4
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Tennessee Retina
- Target Recruit Count
- 22
- Registration Number
- NCT03468296
- Locations
- 🇺🇸
Tennessee Retina, Nashville, Tennessee, United States
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Tennessee Retina
- Target Recruit Count
- 10
- Registration Number
- NCT01857544
- Locations
- 🇺🇸
Tennessee Retina, PC, Nashville, Tennessee, United States
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
Phase 4
- Conditions
- Pigment Epithelial DetachmentAge Related Macular Degeneration
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Tennessee Retina
- Target Recruit Count
- 30
- Registration Number
- NCT01670162
- Locations
- 🇺🇸
Pacific Eye Associates, San Fransisco, California, United States
🇺🇸Retina Associates of Kentucky, Lexington, Kentucky, United States
🇺🇸Tennessee Retina, P.C., Nashville, Tennessee, United States
News
Real-World Study Confirms Safety and Efficacy of Aflibercept Biosimilar Pavblu in 6,313 Patients
A large real-world study of 7,773 eyes from 6,313 patients treated with Pavblu (aflibercept-ayyh) showed stable vision outcomes with no unexpected safety concerns across 255 locations nationwide.